Anyone notice the 2 highest volume days in over a month were today and last Friday. Buyers coming in on Friday in case of weekend announcement ?
e ive raised my numbers on acad. im now at $70-$110
My opinion for an ACAD buy out is that $60 per share is not enough. (I would be glad with $60) but, if Nuplazid continues to get approved for other illnesses, they buy out should be more like $100 per share. I could also see ACAD going it alone and not doing a buy out. Whether or not ACAD gets bought out, I can see Nuplazid becoming a new, primary treatment standard in multiple use cases and not a second, third, or addition too another medication.
Who gets bought out first ACAD or OMER?
These ups and downs create mystery.
whoop whoop! $60/share
CT order filed with SEC today....
im betting 100% on buy out i got a dollar
$ACAD management preparing for the #buyout by $PFE $AZN #CEO gets stock option for 243,750 shares exercisable at $35.80 (will vest on b/o)
you sign a deal with rest of world we go to $60 a share , come on man!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
Landmark M&A Deals Continue to Shape Big Pharma
8:30 am ET September 6, 2017 (PR Newswire)
(This is a small section from the above article) In both of these cases, high-dollar acquisitions were fueled by strong intellectual property positions targeting inviting markets within the pharmaceutical industry. This trend rings true when studying other upstart companies that could be in line for big time buyouts. A buyout of ACADIA Pharmaceuticals, Inc. (NASDAQ: ACAD) has been rumored for months, with the company having reportedly received an offer from AstraZeneca in February and interest from Pfizer related to its lead product NUPLAZID(R), the only significant compound in the company's development pipeline. Approved by the FDA for the treatment of hallucinations and delusions associated with Parkinson's disease, NUPLAZID(R) is currently in late stage trials for similar symptoms in Alzheimer's and schizophrenia, giving it the potential to address a massive and growing global market. The company's stock closed at $36.16 on September 1, and reports from Seeking Alpha suggest that ACADIA's management team is pushing for a substantial premium for a potential buyout in the range of $55 to $60 a share.
Market report: AstraZeneca in spotlight as traders revive bid chatter
Rumours resurfaced today that drugs giant AstraZeneca is preparing to go on the takeover trail. Speculation in the City suggested the FTSE 100 giant is preparing to swoop on Acadia Pharmaceuticals, a San Diego-based firm listed on Nasdaq with a marke
I have been long for many years but all these articles today from Margret Patrick from unknown Market Realist carry's zero weight. another pump and dump. Now on the potential AZ take over hopefully that has some legs.
Nuplazid Expected to Become a Leading Central Nervous System Drug - Market Realist
On April 29, 2016, the FDA approved Acadia Pharmaceuticals’ (ACAD) Nuplazid (pimavanserin) as a first therapy for treating patients with Parkinson’s disease (or PD) psychosis.
Sweet. Hurricane party my house. Windermere Florida. Path has it going right owner is 2am Sunday. Have to love Florida .. 2004 Charlie came right up I4 our primary highway I was outside and the winds really do hold you up. My first hurricane. We had 4 that year. I was ok I saw one no more please. Have to laugh. My 5 year old a little scared. Acad looking great!